FOR CLINICIANS
Maximize patient survival rates with an assessment of the tumor immune response using Immunoscore®, an in vitro diagnostic test that measures the patient’s immune response at the tumor site.
IMMUNOSCORE IN:
FOR BIOPHARMA PARTNERS
Gain actionable insight to advance your biomarker, companion diagnostics and therapeutic clinical trials with our multi-omic analysis of the tumor immune response and unique Immunogram report.
FOR PATIENTS
Find out how Immunoscore® can help your doctor develop a treatment plan personalized for you, based on your unique tumor immune response.
PATIENT INFORMATION FOR:
FOR IVD PARTNERS
Turn our experience into your success by partnering with Veracyte for any or all stages of your IVD development and manufacturing processes.
'I think now we have got the tools on hand to help us personalize treatment for patients, and one of those tools would be the Immunoscore®'
Dr Su Pin Choo
Curie Oncology, Singapore
ABOUT US
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our immuno-oncology diagnostic products and services are used to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.
Leveraging the pioneering work of Dr. Jérôme Galon, the company provides a unique range of immune scoring solutions, including the Immunoscore® assay for assessing the immune contexture of a tumor.
Improving patient’s lives today and into the future, Veracyte translates the complexities of the tumor immune response into a clear path forward.
100+
Patients tested/week
40
Biopharma partners
27
Scientific publications
